Join to View Full Profile
319 S Manning BlvdSte 301Albany, NY 12208
Phone+1 518-458-1390
Fax+1 518-459-3271
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joyce Barlin, MD is an obstetrician/gynecologist in Albany, New York. She is currently licensed to practice medicine in New York.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Gynecologic Oncology, 2011 - 2014
Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 2006 - 2010
Albany Medical CollegeClass of 2006
Certifications & Licensure
NY State Medical License 2010 - 2027
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- 1 citationsENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic ther...Ignace Vergote, Alejandro Perez Fidalgo, Giorgio Valabrega, Bradley J Monk, Thomas Herzog
International Journal of Gynecological Cancer. 2024-08-05 - Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.Omali Pitiyarachchi, Peter J Ansell, Robert L Coleman, Minh H Dinh, Laura Holman
Gynecologic Oncology. 2024-08-01 - 3 citationsLunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel ...Joyce N Barlin, Barb Mahar, Ashar Ata, Beatrice Cormier, David Michelin
Gynecologic Oncology. 2024-01-01
Press Mentions
UPDATE - OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian CancerDecember 30th, 2022
